Orforglipron is an investigational oral GLP-1 receptor agonist being studied for type 2 diabetes and obesity. Unlike injectable GLP-1 compounds such as semaglutide, it’s designed for convenient once-daily oral dosing. Orforglipron is researched for its potential to support significant weight loss and improve blood sugar control, all without injections.
Key information and effects
- Promotes significant weight reduction by suppressing appetite and slowing gastric emptying.
- Enhances insulin secretion and reduces glucagon, improving glycemic control.
- Eliminates injections, potentially improving adherence.
Disclaimer: This product is for laboratory research purposes only. Not for human or animal consumption. Cap colour subject to change.
Reconstitution
Reconstitution is the laboratory process of dissolving a lyophilized (freeze-dried) research compound in a suitable solvent, most commonly bacteriostatic water, to prepare a solution for research use.
Use our Peptide Reconstitution Calculator to work out the solvent volume and concentration for your research parameters.
For laboratory and research use only. Not for human or animal consumption.
Storage
Lyophilized research peptides are generally most stable when stored frozen (around -20 °C), sealed, and protected from light and humidity. Refer to the Certificate of Analysis and product documentation for any compound-specific handling notes.
Once reconstituted, stability and handling vary by compound. Consult the peer-reviewed literature specific to the material you are working with. Minimise repeated freeze-thaw cycles to preserve sample integrity.
For laboratory and research use only. Not for human or animal consumption.
Reviews
There are no reviews yet.